Connect with us

Hi, what are you looking for?

Press Release

Mile High Labs Files Type II Drug Master File with FDA for CBD Isolate


Mile High Labs continues to build its pharmaceutical-channel capabilities with a Type II DMF for CBD Isolate

LOVELAND, Colo., Nov. 19, 2026 /PRNewswire/ — Mile High Labs, a global leader in hemp-derived cannabinoid ingredients, today announced that it has filed a Type II Drug Master File (DMF #044151) with the U.S. Food and Drug Administration for its CBD Isolate, a 98% cannabidiol isolate. The file was submitted on October 2, 2026.

Companies developing drug products can reference DMF #044151 in their own FDA submissions through a Letter of Authorization from Mile High Labs.

“This filing reflects how we have always run this business,” said John Davis, Chief Operating Officer of Mile High Labs. “As our industry has matured over the past decade, investing in quality has remained our true north at Mile High Labs, enabling us to bring our cannabinoid ingredients into highly regulated markets around the world. Our Type II Drug Master File for CBD Isolate represents an important milestone in our ongoing advancement within the pharmaceutical channel, building on a unified quality system that already supplies consumer and regulated medicinal products. As we continue to expand our pharmaceutical capabilities and regulatory readiness, we’re excited to be preparing for an FDA inspection and strengthening our ability to serve drug developers in the U.S. and abroad.”

The file is expected to appear on FDA’s public list of Drug Master Files in its next quarterly update.

About Mile High Labs

For over 10 years, Mile High Labs has been committed to high-quality hemp-derived cannabinoid ingredients, supplying brands and formulators in the United States, United Kingdom, European Union, Japan and other regulated markets. Based in Loveland, Colorado, the company’s portfolio includes CBD, CBG, CBN and CBC isolates, distillates and water-soluble formats.

https://www.prnewswire.com/news-releases/mile-high-labs-files-type-ii-drug-master-file-with-fda-for-cbd-isolate-302946042.html



Source link

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

strain roundup

Breaking News

  Federal Drug Policy, April 2026: The Operative Architecture of Cannabis Rescheduling, the Psychedelic Therapeutic Acceleration Directive, and the Road to June 29 RN...

cannabis business

As the end of November approaches you can feel the buzz amongst cannabis industry circles about the yearly pilgrimage we all make to Las...

Pot Luck

Digital entertainment offers an extraordinary range of conversations, formats and destinations. For a reader interested in Chinese-language online culture, that variety can be appealing...